Assessing the impact of a safe and equitable biosimilar policy in the United States
An edition of Assessing the impact of a safe and equitable biosimilar policy in the United States (2008)
hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, May 2, 2007.
By United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health
Publish Date
2008
Publisher
U.S. G.P.O.,For sale by the Supt. of Docs., U.S. G.P.O.
Language
eng
Pages
184
Description:
subjects: Biologicals, Pharmaceutical biotechnology, Generic drugs
Places: United States